- Distinct epigenetic mechanisms distinguish TMPRSS2-ERG fusion-positive and -negative prostate cancersJoshi J Alumkal
Oregon Health and Science University, Knight Cancer Institute, Portland, OR 97239, USA
Cancer Discov 2:979-81. 2012..This finding clarifies molecular features of these TMPRSS2-ERG fusion-negative tumors and may have implications for how to treat this prostate cancer subtype...
- Effect of DNA methylation on identification of aggressive prostate cancerJoshi J Alumkal
Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon, USA
Urology 72:1234-9. 2008..DNA methylation of promoter regions leads to gene silencing in many cancers. In this study, we assessed the effect of DNA methylation on the identification of recurrent prostate cancer...
- C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): confirmatory resultsRenee C Prins
Division of Hematology and Medical Oncology, Oregon Health and Science University Sam Jackson Park Rd, Portland, OR 97239, USA
Urol Oncol 30:33-7. 2012..CRP is a readily measurable biomarker that has the potential to improve prognostic models and should be validated in a prospective clinical trial...